` CBIO (Crescent Biopharma Inc (Pre-Reincorporation)) vs S&P 500 Comparison - Alpha Spread

CBIO
vs
S&P 500

Over the past 12 months, CBIO has underperformed S&P 500, delivering a return of -48% compared to the S&P 500's +14% growth.

Stocks Performance
CBIO vs S&P 500

Loading
CBIO
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CBIO vs S&P 500

Loading
CBIO
S&P 500
Difference
www.alphaspread.com

Performance By Year
CBIO vs S&P 500

Loading
CBIO
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Crescent Biopharma Inc (Pre-Reincorporation) vs Peers

S&P 500
CBIO
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Crescent Biopharma Inc (Pre-Reincorporation)
Glance View

Market Cap
173m USD
Industry
Biotechnology

Crescent Biopharma Inc (Pre-Reincorporation) is a US-based company operating in Biotechnology industry. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. Crescent Biopharma Inc., formerly GlycoMimetics, Inc., is a biotechnology company. The firm is engaged in advancing novel precision-engineered molecules to advance care for patients with solid tumors. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads for undisclosed targets. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.

CBIO Intrinsic Value
28.31 USD
Undervaluation 56%
Intrinsic Value
Price
Back to Top